About
Targeted Radiotherapy
Areas of Focus
Categories
Biologics & BiopharmaceuticalRadiopharmaceuticalsNJ, NY, PA
Team (14)
Adeela Kamal, PhD
Executive Vice President, Head of Research and Development
Actinium Pharmaceuticals
executive
Ajit Shetty, Ph.D.
Director
Actinium Pharmaceuticals
team_member
C. David Nicholson, B.S., Ph.D
Lead Independent Director
Actinium Pharmaceuticals
lead_independent_directorboard_member
Dhiren Patel
Vice President, Clinical Development – Solid Tumors
Actinium Pharmaceuticals
executive
Gary Siegel
Vice President, Controller
Actinium Pharmaceuticals
executive
Jeffrey W. Chell, M.D.
Director
Actinium Pharmaceuticals
team_member
Clinical Trials (9)
View allTotal Trials
9
As Lead Sponsor
6
As Collaborator
3
Total Enrollment
616
By Phase
PHASE2/PHASE3: 1PHASE1: 3PHASE1/PHASE2: 4PHASE3: 1
By Status
RECRUITING: 2COMPLETED: 2NOT_YET_RECRUITING: 1WITHDRAWN: 1UNKNOWN: 1TERMINATED: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline9 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
Today
Hover over trial bars to see details
Recent Trials
NCT07157514Lead Sponsor
Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML
PHASE2/PHASE3Not yet recruiting
306 participants
Started: Jan 31, 2026 · Completed: Feb 28, 2034
NCT07015684Collaborator
131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)
PHASE1Recruiting
24 participants
Started: Apr 28, 2025 · Completed: Mar 12, 2032
NCT06768905Collaborator
Study of IOMAB-ACT Followed by CAR-T Cell Therapy for Patients Relapsed or Refractory (Diffuse Large B-cell Lymphoma
PHASE1/PHASE2Recruiting
30 participants
Started: Apr 25, 2025 · Completed: May 31, 2030
NCT03932318Lead Sponsor
Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
PHASE1/PHASE2Withdrawn
Started: Mar 31, 2023 · Completed: Sep 30, 2024
NCT03867682Lead Sponsor
Venetoclax and Lintuzumab-Ac225 in AML Patients
PHASE1/PHASE2Unknown
38 participants
Started: Jan 15, 2020 · Completed: Jun 30, 2024
Locations (1)
Headquarters
New York, NY, United States
Map
Loading map...